AptarGroup Is Maintained at Outperform by Baird
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $185
AptarGroup Analyst Ratings
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $185
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating
Bank of America Securities Sticks to Its Buy Rating for AptarGroup (ATR)
DBS Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $200
AptarGroup Upgraded to Buy From Hold at DBS Bank
AptarGroup Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $185
Wells Fargo Sticks to Their Buy Rating for AptarGroup (ATR)
AptarGroup Analyst Ratings
Jefferies Initiates AptarGroup(ATR.US) With Buy Rating, Announces Target Price $215
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $174
AptarGroup: Hold Rating Justified by Solid Pharma Performance Amidst Growth and Margin Challenges
Baird Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $170
AptarGroup's Strong Market Position and Growth Potential Affirm Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)